Early stopping of a clinical trial when there is evidence of no treatment benefit: Protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project

Controlled Clinical Trials

Volumn 19, Issue 6, 1998, Pages 575-588

  Dignam, James J ^a,c   Bryant, John ^a   Wieand, H Samuel ^a   Fisher, Bernard ^b   Wolmark, Norman ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c NSABP Foundation Inc   (United States)

Author keywords

Bayesian methods; Breast cancer; Clinical trials; Data monitoring; Stochastic curtailment; Stopping rules; Tamoxifen

Indexed keywords

ESTROGEN RECEPTOR; PLACEBO; TAMOXIFEN;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MONITORING; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; ATTITUDE OF HEALTH PERSONNEL; BAYES THEOREM; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; TAMOXIFEN; TREATMENT FAILURE;

EID: 0032427758     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(98)00041-5     Document Type: Article

References (26)

1. 1. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-1542.
2. 2. Lan KKG, Simon R, Halperin M. Stochastically curtailed tests in long-term clinical trials. Commun Stat Sequential Anal 1991;1:207-219.
3. 3. Wieand S, Schroeder G, O'Fallon JR. Stopping when the experimental regimen does not appear to help. Stat Med 1994;13:1453-1458.
4. 4. Spiegelhalter DJ, Freedman LS, Parmar MKB. Bayesian approaches to randomized trials (with discussion). J R Stat Soc Ser A 1994;157:357-416.
5. 5. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543-1549.
6. 6. Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996;88:1834-1839.
7. 7. Fisher B, Costantino J, Redmond C, et al. A randomized trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 1989;320:479-484.
8. 8. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Controlled Clin Trials 1984;5:348-361.
9. 9. Anonymous. National Cancer Institute Clinical Announcement: Adjuvant Therapy of Breast Cancer - Tamoxifen Update. November 30, 1995. Bethesda MD: National Institutes of Health, 1995.
10. 10. Halperin M, Lan KKG, Ware JH, et al. An aid to data monitoring in long-term clinical trials. Controlled Clin Trials 1982;3:311-323.
11. 11. Davis BR, Hardy RJ. Upper bounds for type I and type II error rates in conditional power calculations. Commun Stat Theory Meth 1991;19:3571-3584.
12. 12. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: conditional or predictive power? Controlled Clin Trials 1986;7:8-17.
13. 13. Jennison C, Turnbull BW. Statistical approaches to interim monitoring of medical trials: a review and commentary. Stat Sci 1990;5:299-317.
14. 0 embedded in sequential tests. Stat Med 1997;16:465-477.
15. 15. Freedman LS, Spiegelhalter DJ, Parmar MKB. The what, why and how of Bayesian clinical trials monitoring. Stat Med 1994;13:1371-1383.
16. 16. Berry DA, Stangl DK. Bayesian Biostatistics. New York: Marcel Dekker; 1996.
17. 17. Peto R. Five years of tamoxifen - or more? J Natl Cancer Inst 1996;88:1791-1793.
18. 18. Swain SM. Tamoxifen: the long and short of it. J Natl Cancer Inst 1996;88:1510-1512.
19. 19. DeMets DL, Ware JH. Asymmetric group sequential boundaries for monitoring clinical trials. Biometrika 1982;69:661-663.
20. 20. Pampallona S, Tsiatis AA. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis. J Stat Plan Infer 1994;42:19-35.
21. 21. Whitehead J, Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983;39:227-236.
22. 22. DeMets DL. Challenges in clinical trials for the year 2000 and beyond. Second Joint Meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics, Boston, MA, July 6-10, 1997.
23. 23. Parmar MKB, Ungerleider RS, Simon R. Assessing whether to perform a confirmatory randomized clinical trial. J Natl Cancer Inst 1996;88:1645-1651.
24. 24. Berry DA. When is a confirmatory randomized clinical trial needed? J Natl Cancer Inst 1996;88:1606-1607.
25. 25. Stewart HJ, Forrest AP, Everington D. Randomized trial of five years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group. Br J Cancer 1996;74:797-799.
26. 26. Tormey DC, Gray R, Falkson HC. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node positive breast cancer. J Natl Cancer Inst 1996;88:1828-1833.